Evidence map›Paper›PMID 40225466›Full record

ArticleCureus2025

A Case of Systemic Lupus Erythematosus With Sole Anti-phosphatidylserine/Prothrombin Complex Antibodies Complicated by Vertebral Artery Dissection.

Hayato Shimizu, Hiroaki Nishioka

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hayato ShimizuDepartment of General Internal Medicine, Kobe City Medical Center General Hospital, Hyogo, JPN.
Hiroaki NishiokaDepartment of General Internal Medicine, Kobe City Medical Center General Hospital, Hyogo, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebrovascular diseases commonly complicate systemic lupus erythematosus (SLE); however, vertebral artery dissection is rare. Although cerebrovascular diseases in SLE are often associated with antiphospholipid antibodies (aPL), such as lupus anticoagulant (LAC), anticardiolipin antibodies (aCL), and anti-β2 glycoprotein-I antibodies, reports of cases with sole positive anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) are also rare. Herein, we report the case of a 44-year-old woman with SLE who had sole positive aPS/PT results and presented with vertebral artery dissection. The patient, who had previously undergone bypass surgery of the right superficial temporal and middle cerebral arteries for moyamoya vessels, was found to have an asymptomatic left vertebral artery dissection during a follow-up examination. The patient also had a malar rash. Laboratory examination revealed hypocomplementemia and positive results for antinuclear and anti-Smith antibodies. LAC, aCL, and anti-β2 glycoprotein-I antibodies were negative; however, aPS/PT of immunoglobulin G was positive. The patient was diagnosed with SLE with sole positive aPS/PT result complicated by left vertebral artery dissection and moyamoya vessels. We initiated treatment with methylprednisolone pulse therapy, followed by oral prednisolone and intravenous cyclophosphamide. The patient's condition improved without sequelae. This case suggests that even though patients with SLE presenting with vascular complications lack LAC, aCL, and anti-β2 glycoprotein-I antibodies, other aPLs should be investigated.

Indexed as

anti-phosphatidylserine/prothrombin complex antibodiesantiphospholipid antibodies (apl)systemic lupus erythematosusvasculopathyvertebral artery dissection

Identifiers

PMID40225466
PMCPMC11985361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.